REMS: Is it the end of the world as we know it?
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Add this Podcast feed to your media player
Click Here To Listen to More of the ABSG Podcast Series
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.